[Development of novel immune therapies for solid tumors: phase I clinical trials in a single institute]

Rinsho Ketsueki. 2012 May;53(5):487-92.
[Article in Japanese]
No abstract available

Publication types

  • Review

MeSH terms

  • Antigens, Neoplasm / immunology*
  • Cancer Vaccines
  • Clinical Trials, Phase I as Topic*
  • Cyclophosphamide
  • DNA-Binding Proteins / immunology
  • DNA-Binding Proteins / therapeutic use
  • Humans
  • Immune Tolerance
  • Immunosuppressive Agents
  • Immunotherapy / methods*
  • Immunotherapy, Adoptive
  • Neoplasms / therapy*
  • Oncogene Proteins / immunology
  • Oncogene Proteins / therapeutic use
  • Peptides / immunology*
  • T-Lymphocytes, Regulatory / immunology
  • Ubiquitin-Protein Ligases

Substances

  • Antigens, Neoplasm
  • Cancer Vaccines
  • DNA-Binding Proteins
  • Immunosuppressive Agents
  • Oncogene Proteins
  • Peptides
  • Cyclophosphamide
  • RNF43 protein, human
  • Ubiquitin-Protein Ligases